GKV Capital Management’s Edwards Lifesciences EW Stock Holding History

GKV Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Hold	11,335	–	–	0.33%	56
2026 Q1	$908K	Sell	11,335 -1,420	-11%	-$117K	0.34%	58
2025 Q4	$1.09M	Hold	12,755	–	–	0.41%	51
2025 Q3	$992K	Buy	12,755 +260	+2%	+$20.3K	0.39%	52
2025 Q2	$977K	Hold	12,495	–	–	0.43%	50
2025 Q1	$906K	Buy	12,495 +200	+2%	+$14.3K	0.45%	49
2024 Q4	$910K	Buy	+12,295	New	+$861K	0.37%	54

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

GKV Capital Management's EW Position: Q2 2026 in Review

GKV Capital Management held its Edwards Lifesciences (EW) position steady in Q2 2026 at 11,335 shares worth $1.03M. The position accounts for 0.33% of the portfolio, ranked #56.

GKV Capital Management first reported a position in EW in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.09M in Q4 2025. 592 funds tracked by Wall St. Rank hold EW as of Q2 2026.

GKV Capital Management held 11,335 shares of Edwards Lifesciences worth $1.03M as of Q2 2026.
GKV Capital Management left its Edwards Lifesciences share count unchanged in Q2 2026.
Edwards Lifesciences made up 0.33% of GKV Capital Management's portfolio in Q2 2026, its #56 holding.
GKV Capital Management first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 7 quarters since.
GKV Capital Management's Edwards Lifesciences position peaked at $1.09M in Q4 2025.
592 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on GKV Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.